MCRB - Seres Therapeutics Molecular Data On SER-109 Looks Good
- Seres announces new molecular data from SER-109 Phase 3 ECOSPOR III trial at IDWeek 21.
- Ferring Pharmaceuticals subsidiary Rebiotix has a C. difficile recurrence treatment, RBX2660, in Phase 3 trials, although RBX2660 is delivered as an enema rather than tablet form.
- Rebiotix has presented similar molecular data to Seres on its RBX2660 product for preventing C. difficile recurrence.
- The new data from Seres supports that SER-109 remains on track for FDA approval mid-2022.
For further details see:
Seres Therapeutics Molecular Data On SER-109 Looks Good